ω-3 PUFA for Secondary Prevention of White Matter Lesions and Neuronal Integrity Breakdown in Older Adults: A Randomized Clinical Trial.

ω-3 PUFA Effects on Primary and Secondary Outcomes by APOE Genotype Under ITT The mean annual increase in WMLs in APOE*E4 carriers treated with ω-3 vs APOE*E4 carriers treated with placebo was lower but did not reach statistical significance (0.04 cm 3 [95% CI, −0.04 to 0.12 cm 3 ] in the ω-3 group vs 0.11 cm 3 [95% CI, 0.04 to 0.17 cm 3 ] in the placebo group; P = .15).

also in 111,027 other papers

This may explain why the ITT analysis failed to reach statistical significance for the primary outcome of annual WML, secondary outcome of DTI-FA, and exploratory outcomes of DTI-radial diffusivity and mean diffusivity in the ω-3–treated group.

also in 6,035 other papers